Investors

Media Coverage

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Media Coverage

Joseph Tucker – Drugs for Neuroplasticity [The Mindfulness Experience Podcast]

November 4, 2023

Psilocin prodrug receives USPTO development approval [Psychedelic Health]

November 2, 2023

Aligning financial plans to long-term goals [The CFO]

October 19, 2023

Has British biotech outgrown the Square Mile? [Proactive]

October 5, 2023

Biotech firm receives patent for psilocybin-derived mental health therapeutics [Helio]

October 2, 2023

Psilocybin-Based Drug Candidate Gains Patent [High Times]

October 2, 2023

U.S. approval for psychedelic drug MDMA nears after success in clinic [Labiotech]

September 22, 2023

Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here [Benzinga]

September 22, 2023

Enveric Receives Patent For Psilocybin Molecules [Green Market Report]

September 20, 2023

NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics

May 11, 2022

1
2
3
…
7
›

Company

Team

Pipeline

Investors

Contact

Sign Up for Updates

© 2023 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.